ESC 365 - Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

EAPC Premium Access

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

Session: Poster Session 1 - Lipids

Topic: Lipids

Speaker: Mr M. Poudel (Bielefeld, DE)

Event: EuroPrevent 2018

Congress Presentation

Add to my library

About the speaker

Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

2 presentations

1 follower

9 more presentations in this session

Lipids - Poster discussant:

Improvement of lipid profile post cardiac rehabilitation according to the patient's level of risk in a tertiary hospital

Speaker: Doctor A. Chauca Tapia (Girona, ES)

Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting

Speaker: Mr M. Poudel (Bielefeld, DE)

Anti-PCSK9 in everyday clinical practice

Speaker: Doctor R. Cadenas Chamorro (Madrid, ES)

Evaluation of LDL cholesterol level in patients with coronary artery disese after cardiac rehabilitation

Speaker: Professor N. Mouine (Rabat, MA)

Access the full session

Poster Session 1 - Lipids

Speakers: Mr M. Poudel, Doctor A. Chauca Tapia, Mr M. Poudel, Doctor R. Cadenas Chamorro, Professor N. Mouine

About the event

EuroPrevent 2018

19 April - 21 April 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources